Work Description

"Survival analyses conducted in an ancillary study of the RACE trial (https://clinicaltrials.gov/ct2/show/NCT01665092) of patients that received either L-carnitine (18g dose) or placebo using a range of pre-treatment serum acetylcarnitine and valine concentrations as measured by LC-MS or NMR, respectively" CSV files: represent the number of at risk subjects for each representative Kaplan Meier analysis (pdf) for each acetylcarnitine (LC-MS) or valine (NMR) concentration scenario (including one for all patients) for patients that received either L-carnitine (18g) or placebo CSV file name: SA-at risk L-carnitine 18g v PL acetylcarnitine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo CSV file name: SA-at risk 35�M L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 35�M or above CSV file name: SA-at risk 30�M L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 30�M or above CSV file name: SA-at risk 21�M L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 21�M or above CSV file name: SA-at risk L-carnitine 18g v PL valine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo CSV file name: SA-at risk 88�M L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 88�M or above CSV file name: SA-at risk 75�M L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 75�M or above CSV file name: SA-at risk 60�M L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 60�M or above PDF files: show the results of the survival analysis for each acetylcarnitine (LC-MS) or valine (NMR) pre-treatment concentration scenario as well as one for all patients that received either L-carnitine (18g) or placebo including the associated statistical analysis PDF name: SA-acylcarnitines-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which acylcarnitine data were obtained PDF name: SA-acetylcarnitine-21�M: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 21�M or above PDF name: SA-acetylcarnitine-30�M: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 30�M or above PDF name: SA-acetylcarnitine-35uM: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 35�M or above PDF name: SA-NMR data-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which NMR data were obtained PDF name: SA-NMR data-valine-60�M: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 60�M or above PDF name: SA-NMR data-valine-75�M: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 75�M or above PDF name: SA-NMR data-valine-88�M: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 88�M or above